Efficacy of topical 5‐aminosalicylate monotherapy in patients with ulcerative proctitis with skip inflammation

In some patients with ulcerative proctitis (UP), skip inflammation is noted in the right side of the colon, but little is known about its clinical course. The aim of this study was to evaluate the clinical course of UP with skip inflammation and the efficacy of topical 5‐aminosalicylate (5‐ASA) monotherapy.

[1]  S. Ishihara,et al.  Appendiceal orifice inflammation is associated with proximal extension of disease in patients with ulcerative colitis , 2016, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[2]  Jin-Ho Kim,et al.  Atypical distribution of inflammation in newly diagnosed ulcerative colitis is not rare. , 2014, Canadian journal of gastroenterology & hepatology.

[3]  T. Kim,et al.  Proximal disease extension and related predicting factors in ulcerative proctitis , 2014, Scandinavian journal of gastroenterology.

[4]  T. Hibi,et al.  Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation – a placebo‐controlled study , 2013, Alimentary pharmacology & therapeutics.

[5]  G. Oster,et al.  Treatment of new‐onset ulcerative colitis and ulcerative proctitis: a retrospective study , 2012, Alimentary pharmacology & therapeutics.

[6]  P. Moayyedi,et al.  Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  E. Cabré,et al.  Long-term outcome of patients with distal ulcerative colitis and inflammation of the appendiceal orifice. , 2011, Journal of gastrointestinal and liver diseases : JGLD.

[8]  D. Rubin,et al.  The Peri-appendiceal Red Patch in Ulcerative Colitis: Review of the University of Chicago Experience , 2010, Digestive Diseases and Sciences.

[9]  R. Odze,et al.  Rectal Sparing and Skip Lesions in Ulcerative Colitis: A Comparative Study of Endoscopic and Histologic Findings in Patients Who Underwent Proctocolectomy , 2010, The American journal of surgical pathology.

[10]  E. Louis,et al.  Maintenance therapy for ulcerative colitis has no impact on changes in the extent of ulcerative colitis. , 2007, Journal of Crohn's & colitis.

[11]  D. Beck,et al.  Discontinuous appendiceal involvement in ulcerative colitis: Pathology and clinical correlation , 1999, Journal of Gastrointestinal Surgery.

[12]  G. Lee,et al.  Clinical Course of Distal Ulcerative Colitis in Relation to Appendiceal Orifice Inflammation Status , 2005, Inflammatory bowel diseases.

[13]  A. Bella,et al.  Oral Mesalazine (5-ASA) Treatment May Protect Against Proximal Extension of Mucosal Inflammation in Ulcerative Proctitis , 2004, Inflammatory bowel diseases.

[14]  M. Mutinga,et al.  The Clinical Significance of Right-sided Colonic Inflammation in Patients with Left-sided Chronic Ulcerative Colitis , 2004, Inflammatory bowel diseases.

[15]  A. Bousvaros,et al.  Pediatric Patients With Untreated Ulcerative Colitis May Present Initially With Unusual Morphologic Findings , 2004, The American journal of surgical pathology.

[16]  M. Tomonaga,et al.  A case of mucosa-associated lymphoid tissue lymphoma of the ampulla of Vater: successful treatment with radiation therapy. , 2003, European journal of gastroenterology & hepatology.

[17]  L. Rodrigo,et al.  MHC class I chain-related gene A transmembrane polymorphism modulates the extension of ulcerative colitis. , 2003, Human immunology.

[18]  L. Good,et al.  Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis , 2000, American Journal of Gastroenterology.

[19]  D. Chang,et al.  Incidence and prevalence of ulcerative colitis in the Songpa-Kangdong District, Seoul, Korea, 1986-1997. , 2000, Journal of gastroenterology and hepatology.

[20]  Hebden,et al.  Limited exposure of the healthy distal colon to orally‐dosed formulation is further exaggerated in active left‐sided ulcerative colitis , 2000, Alimentary Pharmacology and Therapeutics.

[21]  W. Hong,et al.  Appendiceal orifice inflammation as a skip lesion in ulcerative colitis: an analysis in relation to medical therapy and disease extent. , 1999, Gastrointestinal endoscopy.

[22]  P. Marteau,et al.  Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study , 1998, Gut.

[23]  P. Gionchetti,et al.  Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis , 1998, Diseases of the colon and rectum.

[24]  S. Targan,et al.  A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. , 1997, The American journal of gastroenterology.

[25]  C. Bernstein,et al.  Patchiness of mucosal inflammation in treated ulcerative colitis: a prospective study. , 1995, Gastrointestinal endoscopy.